NASDAQ · Health care

Celularity Inc (CELU)

Celularity Inc reported revenue of $26.6M in fiscal 2025, down 51.0% from a year earlier. It posted a net loss of $91.7M. At December 31, 2025 it held $6.2M in cash against $33.8M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on April 30, 2026.

Watch CELU in 60 seconds

Price

$1.38

+4.55% on the day · September 25, 2026

52-week range $0.56 to $2.55

Market cap

$39.9M

Revenue (FY2025)

$26.6M

-51.0% year on year

Net margin

-345.4%

What Celularity Inc does

Celularity Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CELU.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$26.6M	-$61.3M	-$91.7M	-$3.59	n/a
2024	$54.2M	-$38.4M	-$57.9M	-$2.64	-$6.6M
2023	$22.8M	-$192.3M	-$196.3M	-$11.02	-$39.7M
2022	$18M	-$25.6M	$14.2M	$0.95	-$143.1M
2021	$21.3M	-$109.1M	-$100.1M	-$15.73	-$116.3M
2020	$14.3M	-$151.9M	-$208.2M	-$119.38	-$91M

Full financial statements: income, balance sheet and cash flow

A report was expected around August 31, 2026 and is not on file yet.

Estimated from its filing rhythm: about 122 days after its last report of April 30, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where CELU ranks in Health care

Revenue$26.6M

#421 of 646 in Health care · Bottom 35%

Revenue growth-51.0%

#468 of 474 in Health care · Bottom 1%

Net margin-345.4%

#447 of 485 in Health care · Bottom 8%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Celularity Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Other event 8-K
August 14, 2026
Late quarterly report notice NT 10-Q
August 7, 2026
Executive or director change 8-K
July 29, 2026
Stock exchange listing notice 8-K
July 22, 2026
Delisting notice 25-NSE
June 30, 2026
Executive or director change 8-K
June 25, 2026
Executive or director change 8-K
June 23, 2026
Activist stake changed SCHEDULE 13D/A
June 12, 2026
Stock exchange listing notice 8-K
June 3, 2026
Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 25, 2026. Insider transactions on SEC

Insider trades

What the people running Celularity Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CELU

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Lim Kok Thay13D, may seek influence with 3 related filers	41%	14,138,161	July 28, 2025
Philip & Daniele Barach Family Trust13D, may seek influence with 2 related filers	15.8%	5,514,686	June 23, 2026

Latest filings below 5%: Lincoln Alternative Strategies LLC 0% (February 11, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CELU

What does Celularity Inc do?

Celularity Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CELU.

Is Celularity Inc profitable?

No. In fiscal 2025 it reported a net loss of $91.7M on revenue of $26.6M.

How much revenue does Celularity Inc make?

In fiscal 2025 Celularity Inc reported revenue of $26.6M. That is 51.0% less than a year earlier.

When did Celularity Inc last report?

Its most recent periodic report is the annual report (10-K) filed on April 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from September 25, 2026.

Similar companies

Compare CELU with

Compare CELU with any company

Follow CELU

Get an email when Celularity Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow CELU: get an email when it files

Where the numbers come from

Financial figures are the values Celularity Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.